insitro and AstraZeneca team up on AI drug discovery for MASH and cardiomyopathies
AI drug discovery company insitro has signed a worldwide exclusive research collaboration with AstraZeneca to find new targets and therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. insitro will receive $40 million upfront and is eligible for up to approximately $1.46 billion in potential milestones.
- insitro and AstraZeneca signed a worldwide exclusive research collaboration on MASH and cardiomyopathies.
- insitro receives $40 million upfront and is eligible for up to approximately $1.46 billion in milestones, plus single-digit royalties.
- insitro will use its Virtual Human platform to advance AstraZeneca-nominated targets to development candidate.
- AstraZeneca will lead clinical development, regulatory work, and commercialization.
Deal terms and division of work
According to insitro, the agreement gives the company $40 million upfront and eligibility for up to approximately $1.46 billion in potential discovery, development, and commercial milestones. It also includes single-digit royalties based on potential global commercial sales.
The work is split along clear lines. insitro will apply its Virtual Human platform to identify causal disease biology in both indications. It will also advance AstraZeneca-nominated targets from discovery through to development candidate. AstraZeneca will lead all clinical development, regulatory work, and commercialization activities.
Why these two diseases
The companies point to patient heterogeneity as the core problem. In MASH and cardiomyopathies, a single diagnostic label spans patients whose underlying biology differs. According to insitro, this heterogeneity has made the diseases difficult to treat, and it is the condition under which the company's existing machine learning capabilities on human data are most useful.
Daphne Koller, Ph.D., founder and CEO of insitro, described both as "prevalent, underdiagnosed diseases where high-content data holds immense potential for uncovering disease drivers." She said the platform "simultaneously deconvolutes disease biology and identifies causal drivers of disease pathologies."
Sharon Barr, Executive Vice President and Head of BioPharmaceuticals R&D at AstraZeneca, said that selecting the right target is one of the most critical decisions in R&D. She said the collaboration reflects AstraZeneca's commitment to using AI "to identify the biological drivers of disease."
About insitro and its pipeline
insitro describes itself as a physical AI company focused on causal human biology. According to the company, since 2018 it has built what it calls the world's largest integrated multi-modal corpus of human and cellular data. It also describes the Virtual Human as a genetically anchored AI engine, and the TherML platform as the system that designs medicines against the causal drivers identified.
The company says it is advancing a pipeline of nine programs. These include genetic master regulators of liver fat and fibrosis that it expects to enter the clinic in early 2027, and an oligonucleotide therapy with disease-modifying potential in 97% of ALS patients. insitro says it is backed by more than $750M in capital from investors including a16z, ARCH, BlackRock, CPP, Deviation, Foresite, GV, T. Rowe Price, and Temasek, and that it already collaborates with BMS, Lilly, and Gilead.
What it means
For insitro, the agreement adds a large pharmaceutical partner to its existing collaborations and ties a substantial share of its potential income to milestones rather than upfront cash. For AstraZeneca, it provides AI-driven target discovery in two conditions where patient subgroups complicate drug development. Koller said the partnership pairs insitro's biological precision with AstraZeneca's pharmaceutical expertise and scale, with potential for faster advancement of programs to patients. The source gives no timelines for specific programs under the collaboration.
